Medical Policy:

Cryosurgical Ablation for Prostate Cancer

POLICY NUMBER	LAST REVIEW
MG.MM.SU.53cC	October 14, 2022

Definitions

Cryosurgery (aka cryotherapy or cryoablation) is a minimally invasive therapy performed with ultrasound guidance that destroys prostate tumor tissue through local freezing. The modality involves either complete or focal ablation (subtotal cryoablation) only targeting diseased tissue while leaving normal tissue intact.

Guideline

Cryosurgery is considered medically necessary as salvage therapy for prostate cancer recurrence after treatment with radiation when disease is localized to one lobe of the prostate.

Limitations and Exclusions

Salvage therapy is not considered medically necessary when radiation was not utilized as a primary therapy.

Cryosurgery as a primary treatment modality is not considered medically necessary because it is not supported by the National Comprehensive Cancer Network® (NCCN).

Procedure Codes

55873	Cryosurgical ablation of the prostate (includes ultrasonic guidance and monitoring)

ICD-10 Diagnoses

C61	Malignant neoplasm of prostate
D07.5	Carcinoma in situ of prostate

References

Bahn D, et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 2012 Jul;62(1):55-63.

BlueCross BlueShield Association (BCBS), Technology Evaluation Center. Cryoablation for the primary treatment of clinically localized prostate cancer. TEC Assessment Program. Chicago IL: BCBSA; 2001;16(6).

BlueCross BlueShield Association Technology Evaluation Center (TEC). Cryoablation for the primary treatment of clinically localized prostate cancer. 2001 Sep;16(6).

Cheetham P, et al. Long term cancer-specific and overall survival for men followed more than 10 years after primary and salvage cryoablation of the prostate. J Endourol 2010 Ju;24(7):1123-9.

Chou R, et al. Treatments for localized prostate cancer: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation . Rockville (MD) 2011.

Dhar N, et al. Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients traced with the COLD Registry. BJU Int 2011 Aug;108(4):508-12.

Donnelly BJ, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010;116:323–30.

Durand M, et al. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. BJU Int 2014 Jan;113(1):56-64.

Li YH, et al. Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry. Prostate 2015 Jan;75(1):1-7.

Malcolm JB, et al. Quality of life after open or robotic prostatectomy cryoablation or brachytherapy for localized prostate cancer. J Urol 2010 May;183:1822-9.

Mouraviev V, et al. Cryoablation for locally recurrent prostate cancer following primary radiotherapy. Eur Urol 2012;61:1204-11.

National Comprehensive Cancer Network. Prostate Cancer Guidelines. V1.2022. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed October 18, 2022.

National Institute for Health and Clinical Excellence (NICE). Cryotherapy as a primary treatment for prostate cancer. Interventional Procedure Guidance 145. London, UK: NICE; November 2005.

National Institute for Health and Clinical Excellence (NICE). Cryotherapy for recurrent prostate cancer. Interventional Procedure Guidance No. 119. London, UK: NICE; May 2005.

Parekh A, et al. Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: a systematic review. Semin Radiat Oncol 2013 Jul;23(3):222-34.

Punnen S, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol 2013 Dec;64(6):905-15.

Shelley M, et al. Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev 2007;(3):CD005010. Ullal AV, et al. A report on major complications and biochemical recurrence after primary and salvage cryosurgery for prostate cancer in patients with prior resection of benign prostatic hyperplasia: a single-center experience. Urology 2013 Sep;82(3):648-52.

Ward JF, et al. Cryoablation for locally advanced clinical stage T3 prostate cancer: a report from the Cryo-On-Line Database (COLD) Registry. BJU Int 2014 May;113(5):714-8.

Xiong T, et al. Comparative efficacy and safety of treatments for localized prostate cancer: an application of network meta-analysis. BMJ Open 2014;4:e004285.

Revision History

Oct. 8, 2021	Updated positive coverage statement to communicate cryotherapy applicability to one lobe, post-radiation, and removed test parameter prerequisites of stage T2b or below, and PSA of < 8 ng/mL
Nov. 11, 2019	Removed Gleason Score prerequisite
Sept. 13, 2019	Connecticare adopts the clinical criteria of its parent corporation EmblemHealth Removed primary treatment as a covered indication